Valve performance matters from day one.

Sustained valve performance† helps keep your patients alive and out of the hospital.1


Exclamation icon Indications, Safety, and Warnings
Valve performance
Durable valve performance, as defined by freedom from bioprosthetic valve dysfunction† (BVD), is critical, regardless of the procedure or platform.1

Evolut™ TAVR - a proven legacy of performance

Poor valve performance† results in worse patient outcomes.1

Poor valve performance results in worse patient outcomes

BVD imparts

50%
relative increase in hazard of any death or rehospitalization at 5 years.1

A proven legacy of performance.

Valve performance starts the day of the procedure and continues for a lifetime.

Evolut™ TAVR delivers superior valve performance‡ in patients with small annulus§ at one year versus SAPIEN™* platform.3
A proven legacy of performance

† Bioprosthetic Valve Dysfunction (BVD)2 defined as: SVD (mean gradient ≥ 10 mmHg increase from 30-day/discharge to last echo AND ≥ 20 mmHg at last echo or new onset/ increase of ≥ moderate intraprosthetic aortic regurgitation), NSVD (severe PPM at 30-day/discharge or severe PVR through 5 years), clinical valve thrombosis, and endocarditis.

‡ Valve performance as defined as freedom from bioprosthetic valve dysfunction (BVD) through 12 months. BVD is defined as a composite including any of the following: hemodynamic structural valve dysfunction (mean gradient ≥ 20 mmHg), non-structural valve dysfunction (severe prothesis-patient mismatch or ≥ moderate aortic regurgitation), clinical thrombosis, endocarditis, and aortic valve reintervention.

§ In patients with small annuli (area ≤ 430 mm2) in all-comers trial, consisting of majority low surgical risk participants (52.1%).


  1. Yakubov SJ, Van Mieghem NM, Oh JK, et al. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. J Am Coll Cardiol. April 8, 2025;85(13):1419–1430.
  2. Adapted from VARC-3 : Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol. 2021;77(21):2717–2746.
  3. Herrmann HC, Mehran R, Blackman DJ, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. June 6 2024;390(21):1959–197.
  4. Kornyeva A, Burri M, Lange R, Ruge H. Self-expanding vs. balloon expandable transcatheter heart valves in small aortic annuli. Front Cardiovasc Med. Aug 3, 2023;10:1175246.

™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

US-CV-2602022 EN 09/2026